Hudson Bay Capital Management
APGE

Hudson Bay Capital Management’s Apogee Therapeutics APGE Stock Holding History

Hudson Bay Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-79,000
Closed -$5.96M – 1390
2025
Q4 		$5.96M Buy
+79,000
New +$4.98M 0.02% 457

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Hudson Bay Capital Management's APGE Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 5,720 shares — an estimated $481K sold.

Hudson Bay Capital Management first reported a position in APGE in Q4 2023 and held it in 2 quarters. The position peaked at $559K in Q4 2023. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 5,720 Apogee Therapeutics shares in Q2 2026, an estimated $481K.
  • Hudson Bay Capital Management first reported a position in Apogee Therapeutics in Q4 2023 and held it in 2 quarters.
  • Hudson Bay Capital Management's Apogee Therapeutics position peaked at $559K in Q4 2023.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.